Gong Mobilization Versus Spencer Technique for Diabetic Frozen Shoulder

March 4, 2026 updated by: Riphah International University

Comparative Effect of Gong Mobilization and Spencer Technique in the Management of Frozen Shoulder Among Diabetic Patients

The aim of this randomized controlled trial is to find the comparative effect of spencer technique and gong mobilization on pain, range of motion and functional disability among diabetic frozen shoulder patients.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Frozen shoulder, also known as adhesive capsulitis, is a common musculoskeletal condition characterized by progressive pain, stiffness, and significant restriction of both active and passive range of motion in the shoulder joint. The condition typically progresses through three stages: the painful or freezing stage, marked by increasing pain and stiffness; the frozen or adhesive stage, where pain may subside but stiffness persists; and the thawing stage, during which mobility gradually improves. Risk factors include age, gender (more common in women), trauma, prolonged immobilization, and systemic conditions such as diabetes mellitus. Studies suggest Gong mobilization may offer superior ROM gains, while the Spencer technique provides significant long-term benefits, especially when combined with conventional therapy. Treatment effectiveness can vary, indicating a need for approaches tailored to individual patient factors and condition stage. This is particularly relevant for diabetic patients, who often experience slower, more complex recoveries.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Islamabad, Punjab Province, Pakistan
        • HBS General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with HbA1c ≥6.5% will be included.
  • Patients diagnosed with frozen shoulder stage II, will be included.

Exclusion Criteria:

  • Receiving other clinical trials that could interfere with the outcomes of this study.
  • Subject with recent history of surgery on affected shoulder
  • Subject with history of any trauma/fracture around shoulder complex
  • Subject with rotator cuff lesion and tendon calcification.
  • Patients contraindicated to joint mobilization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Spencer Technique + Conventional Treatment
The Spencer Technique is an osteopathic shoulder mobilization performed with the patient lying on the unaffected side and the therapist stabilizing the scapula while moving the humerus. It consists of a sequence of seven articulatory steps: shoulder extension, flexion, circumduction with compression, circumduction with traction, abduction with internal rotation, internal rotation (hand behind back), and abduction with external rotation. Each movement is performed rhythmically at the end range to stretch the joint capsule, improve mobility, and reduce pain (Frequency: Over the course of 3 days, the exercise was repeated 3 times per session). Conventional PT: Hot pack = 15 mins, Home Plan: Pendulum Stretch, Cross-Body Arm Reach, Towel Stretch, Finger Walk (Wall Climb), External Rotation Stretch, Shoulder Blade Squeeze, Overhead Shoulder Stretch.
Other: Spencer Technique + Conventional Treatment
The Spencer Technique is an osteopathic shoulder mobilization performed with the patient lying on the unaffected side and the therapist stabilizing the scapula while moving the humerus. It consists of a sequence of seven articulatory steps: shoulder extension, flexion, circumduction with compression, circumduction with traction, abduction with internal rotation, internal rotation (hand behind back), and abduction with external rotation. Each movement is performed rhythmically at the end range to stretch the joint capsule, improve mobility, and reduce pain (Frequency: Over the course of 3 days, the exercise was repeated 3 times per session). Conventional PT: Hot pack = 15 mins, Home Plan: Pendulum Stretch, Cross-Body Arm Reach, Towel Stretch, Finger Walk (Wall Climb), External Rotation Stretch, Shoulder Blade Squeeze, Overhead Shoulder Stretch.
Experimental: Gong Mobilization + Conventional Treatment
The shoulder joint was turned upward as the patient was positioned in a side-lying posture. The patient had a 90-degree abduction of the shoulder to keep the humerus upright, and the elbow was 90 degrees flexed. Now the therapist held one hand of the patient to apply pressure to the humeral head from anterior to posterior while maintaining the position of the elbow at 90 degrees. The therapist then raised their own body while softly pushing on the shoulder joint's articular capsule. To retain the humerus' vertical axis, they achieved this while keeping shoulder abduction and elbow flexion at 90 degrees. The procedure was finished in about two to three minutes, and the articular capsule was gently squeezed for 10-15 seconds, and then relaxed for five seconds. After slightly stretching the capsule, the therapist applied gentle pressure with one hand on the shoulder joint from anterior to posterior. Maitland grades 3,4 then performed and then grade 4 approach for stretching for secs.
Other: Gong Mobilization + Conventional Treatment
The shoulder joint was turned upward as the patient was positioned in a side-lying posture. The patient had a 90-degree abduction of the shoulder to keep the humerus upright, and the elbow was 90 degrees flexed. Now the therapist held one hand of the patient to apply pressure to the humeral head from anterior to posterior while maintaining the position of the elbow at 90 degrees. The therapist then raised their own body while softly pushing on the shoulder joint's articular capsule. To retain the humerus' vertical axis, they achieved this while keeping shoulder abduction and elbow flexion at 90 degrees. The procedure was finished in about two to three minutes, and the articular capsule was gently squeezed for 10-15 seconds, and then relaxed for five seconds. After slightly stretching the capsule, the therapist applied gentle pressure with one hand on the shoulder joint from anterior to posterior. Maitland grades 3,4 then performed and then grade 4 approach for stretching for secs.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
The Shoulder Pain and Disability Index (SPADI)
Time Frame: 3 weeks
It is a self-reported questionnaire designed to measure pain and functional disability in individuals with shoulder conditions, such as frozen shoulder or rotator cuff injuries. It consists of two subscales: pain and disability, providing a comprehensive assessment of shoulder function.
3 weeks
Numeric Pain Rating Scale
Time Frame: 3 weeks
The NPRS is a segmented numeric version of the visual analog scale which is used to assess pain. It scores ranges from 0-10, 0 means No pain and 10 means Severe pain. Patient will be asked to verbally report the pain score.
3 weeks
Goniometer for range of motion
Time Frame: 3 weeks
A goniometer is a standard clinical tool for objectively measuring joint range of motion (ROM). It demonstrates high validity, correlating strongly (r > 0.90) with advanced motion analysis systems. Its reliability is also excellent, with high intra-rater (ICC > 0.90) and inter-rater (ICC 0.85-0.99) scores. This makes it a dependable instrument for both assessing patients and guiding treatment in rehabilitation and research.
3 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Maria khalid, MSOMPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 2, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 25, 2025

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 28, 2025

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 2, 2025

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 4, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/ Afshan Batool 02212

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings